CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 300,789	$ 201,525
Short-term marketable securities	282	0
Accounts receivable	6,743	0
Receivables from collaboration arrangement	65,606	110,711
Inventory	70,807	0
Prepaid expenses	7,932	1,367
Other current assets	2,432	70
Total current assets	454,591	313,673
Property and equipment, net	165	12
Equity and long-term investments	489,111	483,845
Capitalized fees paid to a related party, net	101,062	111,430
Right-of-use assets	3,679	97
Goodwill	15,995	0
Intangible assets	258,489	0
Deferred tax assets, net	0	17,327
Other assets	4,620	11
Total assets	1,327,712	926,395
Current liabilities:
Accounts payable	3,805	27
Accrued personnel-related expenses	6,473	619
Accrued interest payable	5,702	4,152
Deferred revenue	2,849	0
Convertible subordinated notes due 2023, net of issuance costs	96,131	0
Income tax payable	33,804	0
Other accrued liabilities	15,120	1,009
Total current liabilities	163,884	5,807
Long-term debt, net of discount and issuance costs	443,679	394,653
Other long-term liabilities	78,421	0
Deferred tax liabilities	360	0
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding	0	0
Common stock: $0.01 par value, 200,000 shares authorized, 69,776 and 69,566 issued and outstanding as of September 30, 2022 and December 31, 2021 respectively	698	696
Treasury stock: at cost, 32,005 shares as of September 30, 2022 and December 31, 2021, respectively	(393,829)	(393,829)
Additional paid-in capital	1,171,096	1,264,024
Accumulated deficit	(136,597)	(456,148)
Total Innoviva stockholders' equity	641,368	414,743
Noncontrolling interest	0	111,192
Total stockholders' equity	641,368	525,935
Total liabilities and stockholders' equity	$ 1,327,712	$ 926,395